Mediastinal lymph node removal modulates natural killer cell exhaustion in patients with non-small cell lung cancer.
CTLA-4
Cytokines
Natural killer cells
PD-1
VAMLA
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
07
06
2023
accepted:
28
07
2023
medline:
24
11
2023
pubmed:
16
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death globally. In this study, the effect of complete removal of mediastinal lymph nodes by video-assisted mediastinoscopic lymphadenectomy (VAMLA) on natural killer (NK) cell phenotype and functions in patients with NSCLC was evaluated. The study included 21 NSCLC patients (cIA-IVA) undergoing VAMLA staging and 33 healthy controls. Mononuclear cells were isolated from peripheral blood of all participants and mediastinal lymph nodes of the patients. NK cells were analyzed by flow cytometry to define NK subsets, expressions of PD-1, CTLA-4, activating/inhibitory receptors, granzyme A, and CD107a. The plasma levels of soluble PD-1, PDL-1, and CTLA-4 were measured by ELISA. Mediastinal lymph nodes of NSCLC patients had increased ratios of exhausted NK cells, increased expression of PD-1 and IL-10, and impaired cytotoxicity. Mediastinal lymph nodes removal increased CD56
Identifiants
pubmed: 37583002
doi: 10.1007/s12026-023-09410-3
pii: 10.1007/s12026-023-09410-3
doi:
Substances chimiques
Interleukin-10
130068-27-8
CTLA-4 Antigen
0
Programmed Cell Death 1 Receptor
0
CD56 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
959-971Subventions
Organisme : Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi
ID : TOA-2017 20591
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Srivastava S, et al. Chemokines and NSCLC: emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022;86(Pt 2):233–46.
pubmed: 35787939
doi: 10.1016/j.semcancer.2022.06.010
Goldstraw P, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
pubmed: 26762738
doi: 10.1016/j.jtho.2015.09.009
De Leyn P, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787–98.
pubmed: 24578407
doi: 10.1093/ejcts/ezu028
Kuzdzal J, et al. Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study. Lung Cancer. 2021;156:140–6.
pubmed: 33962764
doi: 10.1016/j.lungcan.2021.04.018
Ray MA, et al. Survival after mediastinal node dissection, systematic sampling, or neither for early stage NSCLC. J Thorac Oncol. 2020;15(10):1670–81.
pubmed: 32574595
pmcid: 7787197
doi: 10.1016/j.jtho.2020.06.009
Shen-Tu Y, et al. Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: a 10-year cohort study. Medicine (Baltimore). 2017;96(43):e8356.
pubmed: 29069017
doi: 10.1097/MD.0000000000008356
Turna A, et al. Video-assisted mediastinoscopic lymphadenectomy is associated with better survival than mediastinoscopy in patients with resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146(4):774–80.
pubmed: 23778084
doi: 10.1016/j.jtcvs.2013.04.036
Engin A, et al. Mediastinal lymph node removal ameliorates cytotoxic T-lymphocyte functions in patients with non-small cell lung cancer. Tumori. 2023;109(1):97–104.
pubmed: 34918599
doi: 10.1177/03008916211064643
Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–9.
pubmed: 18650461
pmcid: 2481557
doi: 10.1182/blood-2007-09-077438
Pegram HJ, et al. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216–24.
pubmed: 20567250
doi: 10.1038/icb.2010.78
Esen F, Deniz G, Aktas EC. PD-1, CTLA-4, LAG-3, and TIGIT: the roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. Immunol Lett. 2021;240:15–23.
pubmed: 34599946
doi: 10.1016/j.imlet.2021.09.009
Terren I, et al. NK Cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278.
pubmed: 31616440
pmcid: 6769035
doi: 10.3389/fimmu.2019.02278
Vuletic A, et al. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients. J Surg Res. 2013;183(2):860–8.
pubmed: 23522458
doi: 10.1016/j.jss.2013.02.025
Carrega P, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–75.
pubmed: 18203207
doi: 10.1002/cncr.23239
Cheng M, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230–52.
pubmed: 23604045
pmcid: 4076738
doi: 10.1038/cmi.2013.10
Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.
pubmed: 18425107
doi: 10.1038/ni1582
Khan M, Arooj S, Wang H. NK Cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167.
pubmed: 32117298
pmcid: 7031489
doi: 10.3389/fimmu.2020.00167
Kucuksezer UC, et al. The role of natural killer cells in autoimmune diseases. Front Immunol. 2021;12:622306.
pubmed: 33717125
pmcid: 7947192
doi: 10.3389/fimmu.2021.622306
Sivori S, et al. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430–41.
pubmed: 30778167
pmcid: 6474200
doi: 10.1038/s41423-019-0206-4
Marcenaro E, et al. CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. Eur J Immunol. 2003;33(12):3367–76.
pubmed: 14635045
doi: 10.1002/eji.200324425
Shibuya A, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573–81.
pubmed: 8673704
doi: 10.1016/S1074-7613(00)70060-4
Vitale M, et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol. 2001;31(1):233–42.
pubmed: 11265639
doi: 10.1002/1521-4141(200101)31:1<233::AID-IMMU233>3.0.CO;2-4
Amand M, et al. Human CD56(dim)CD16(dim) cells as an individualized natural killer cell subset. Front Immunol. 2017;8:699.
pubmed: 28674534
pmcid: 5474676
doi: 10.3389/fimmu.2017.00699
Aktas E, et al. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254(2):149–54.
pubmed: 18835598
doi: 10.1016/j.cellimm.2008.08.007
Sorrentino C, et al. Colorectal cancer-associated immune exhaustion involves T and B lymphocytes and conventional NK cells and correlates with a shorter overall survival. Front Immunol. 2021;12:778329.
pubmed: 34975867
pmcid: 8716410
doi: 10.3389/fimmu.2021.778329
Rezaeifard S, et al. NK, NKT and invariant-NKT cells in tumor draining lymph nodes of patients with breast cancer. Iran J Immunol. 2019;16(4):291–8.
pubmed: 31885006
Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–32.
pubmed: 29915296
doi: 10.1038/s41590-018-0132-0
Tabar L, et al. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999;86(3):449–62.
pubmed: 10430253
doi: 10.1002/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.0.CO;2-Q
Niu C, et al. PD-1-positive natural killer cells have a weaker antitumor function than that of PD-1-negative natural killer cells in lung cancer. Int J Med Sci. 2020;17(13):1964–73.
pubmed: 32788875
pmcid: 7415385
doi: 10.7150/ijms.47701
Pesce S, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335-346.e3.
pubmed: 27372564
doi: 10.1016/j.jaci.2016.04.025
Tumino N, et al. Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: functional analysis and expression of PD-1 receptor. Int J Cancer. 2019;145(6):1660–8.
pubmed: 30856277
pmcid: 6767381
doi: 10.1002/ijc.32262
Paz-Ares L, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211.
pubmed: 33476593
doi: 10.1016/S1470-2045(20)30641-0
Hellmann MD, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.
pubmed: 31562796
doi: 10.1056/NEJMoa1910231
Debska-Zielkowska J, et al. KIR receptors as key regulators of NK cells activity in health and disease. Cells. 2021;10(7):1777.
pubmed: 34359951
pmcid: 8303609
doi: 10.3390/cells10071777
Michel T, et al. Human CD56bright NK cells: an update. J Immunol. 2016;196(7):2923–31.
pubmed: 26994304
doi: 10.4049/jimmunol.1502570
Poli A, et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–65.
pubmed: 19278419
pmcid: 2673358
doi: 10.1111/j.1365-2567.2008.03027.x
Okuma Y, et al. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):410-417.e1.
pubmed: 29859759
doi: 10.1016/j.cllc.2018.04.014
Chakrabarti R, Kapse B, Mukherjee G. Soluble immune checkpoint molecules: serum markers for cancer diagnosis and prognosis. Cancer Rep (Hoboken). 2019;2(4):e1160.
pubmed: 32721130
doi: 10.1002/cnr2.1160
Gong B, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216(4):982–1000.
pubmed: 30872362
pmcid: 6446862
doi: 10.1084/jem.20180870
Hatanaka H, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol. 2000;11(7):815–9.
pubmed: 10997808
doi: 10.1023/A:1008375208574
Lee J, et al. Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer. Oncotarget. 2017;8(41):70431–40.
pubmed: 29050291
pmcid: 5642566
doi: 10.18632/oncotarget.19712
Platonova S, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–22.
pubmed: 21708957
doi: 10.1158/0008-5472.CAN-10-4179
Marcon F, et al. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology. 2020;9(1):1845424.
pubmed: 33299656
pmcid: 7714501
doi: 10.1080/2162402X.2020.1845424
Sun C, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology. 2017;6(1):e1264562.
pubmed: 28197391
doi: 10.1080/2162402X.2016.1264562
Andre P, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731-1743.e13.
pubmed: 30503213
pmcid: 6292840
doi: 10.1016/j.cell.2018.10.014
Peng YP, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 2013;11:262.
pubmed: 24138752
pmcid: 3854023
doi: 10.1186/1479-5876-11-262
Koyama-Nasu R, et al. The cellular and molecular basis of CD69 function in anti-tumor immunity. Int Immunol. 2022;34(11):555–61.
pubmed: 35689672
doi: 10.1093/intimm/dxac024
Russick J, et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. J Immunother Cancer. 2020;8(2):e001054.